226 related articles for article (PubMed ID: 25909367)
21. Vismodegib in advanced basal-cell carcinoma.
Henkin RI
N Engl J Med; 2012 Sep; 367(10):970; author reply 970-1. PubMed ID: 22931271
[No Abstract] [Full Text] [Related]
22. Treatment of locally advanced basal cell carcinoma with vismodegib.
Moreiras Arias N; Vázquez Veiga H; Sánchez-Aguilar D
Med Clin (Barc); 2023 May; 160(9):413-414. PubMed ID: 36646552
[No Abstract] [Full Text] [Related]
23. Emergence of a squamous cell carcinoma phenotype following treatment of metastatic basal cell carcinoma with vismodegib.
Iarrobino A; Messina JL; Kudchadkar R; Sondak VK
J Am Acad Dermatol; 2013 Jul; 69(1):e33-4. PubMed ID: 23768306
[No Abstract] [Full Text] [Related]
24. Indications and limitations of vismodegib for basal cell carcinoma.
Yin VT; Sniegowski M; Esmaeli B
JAMA Ophthalmol; 2014 Jul; 132(7):905-6. PubMed ID: 25010179
[No Abstract] [Full Text] [Related]
25. Xanthomatous Dermal Changes in a Patient With Locally Advanced Basal Cell Carcinoma Treated Using Vismodegib.
Smith SDB; Clarke CN; Clark MA; Harker-Murray AK; Sokumbi O
Am J Dermatopathol; 2021 Aug; 43(8):585-587. PubMed ID: 33534208
[TBL] [Abstract][Full Text] [Related]
26. Indications and limitations of vismodegib for basal cell carcinoma--reply.
Gill HS; Moscato EE; Silkiss RZ
JAMA Ophthalmol; 2014 Jul; 132(7):906. PubMed ID: 25010181
[No Abstract] [Full Text] [Related]
27. Complete response is reversible upon vismodegib withdrawal and re-inducible upon vismodegib rechallenge in a patient with locally advanced basal cell carcinoma.
Dessinioti C; Plaka M; Dimitrakopoulou A; Stratigos AJ
J Eur Acad Dermatol Venereol; 2019 May; 33(5):e187-e188. PubMed ID: 30653740
[No Abstract] [Full Text] [Related]
28. Use of vismodegib for the treatment of multiple basal cell carcinomas in a patient with xeroderma pigmentosum.
Soura E; Plaka M; Dessinioti C; Chasapi V; Stefanaki C; Antoniou C; Stratigos A
Pediatr Dermatol; 2018 Nov; 35(6):e334-e336. PubMed ID: 30178564
[TBL] [Abstract][Full Text] [Related]
29. Lichenoid reaction as a potential immune response marker of intratreatment histological response during successful vismodegib treatment for a giant basal cell carcinoma.
Fosko SW; Chu MB; Mattox AR; Richart JM; Burkemper NM; Slutsky JB
Dermatol Ther; 2015; 28(6):359-62. PubMed ID: 26114264
[TBL] [Abstract][Full Text] [Related]
30. [Vismodegib for basal cell carcinoma: targeted therapy in case of locally advanced or metastasised disease].
Reinders MG; Terra JB; Reyners AK; Aarts MJ; de Haas ER; Mosterd K
Ned Tijdschr Geneeskd; 2016; 160():D187. PubMed ID: 28000572
[TBL] [Abstract][Full Text] [Related]
31. Vismodegib granted FDA approval for treatment of basal cell carcinoma.
Oncology (Williston Park); 2012 Feb; 26(2):174, 213. PubMed ID: 22489352
[No Abstract] [Full Text] [Related]
32. Emergence of chemoresistance in a metastatic basal cell carcinoma patient after complete response to hedgehog pathway inhibitor vismodegib (GDC-0449).
Meani RE; Lim SW; Chang AL; Kelly JW
Australas J Dermatol; 2014 Aug; 55(3):218-21. PubMed ID: 25117162
[TBL] [Abstract][Full Text] [Related]
33. Risk of cutaneous squamous cell carcinoma after treatment of basal cell carcinoma with vismodegib.
Bhutani T; Abrouk M; Sima CS; Sadetsky N; Hou J; Caro I; Chren MM; Arron ST
J Am Acad Dermatol; 2017 Oct; 77(4):713-718. PubMed ID: 28780365
[TBL] [Abstract][Full Text] [Related]
34. Vismodegib and surgery combined - effective treatment of locally advanced basal cell carcinoma.
Paulsen JF; Øregaard JS; Nielsen AL; Gehl J; Venzo A
Acta Oncol; 2016 Dec; 55(12):1492-1494. PubMed ID: 27448604
[No Abstract] [Full Text] [Related]
35. A comprehensive review of the role of the hedgehog pathway and vismodegib in the management of basal cell carcinoma.
Erdem GU; Sendur MA; Ozdemir NY; Yazıcı O; Zengin N
Curr Med Res Opin; 2015 Apr; 31(4):743-56. PubMed ID: 25690490
[TBL] [Abstract][Full Text] [Related]
36. Vismodegib in basal cell carcinoma.
Amaria RN; Bowles DW; Lewis KD; Jimeno A
Drugs Today (Barc); 2012 Jul; 48(7):459-67. PubMed ID: 22844657
[TBL] [Abstract][Full Text] [Related]
37. Cannabis for Vismodegib-Related Muscle Cramps in a Patient With Advanced Basal Cell Carcinoma.
Kutiel TS; Vornicova O; Bar-Sela G
J Pain Symptom Manage; 2018 May; 55(5):e1-e2. PubMed ID: 29454899
[No Abstract] [Full Text] [Related]
38. Invasive Basal Cell Carcinoma of the Skin Treated Successfully with Vismodegib: A Case Report.
Awad R; Andrade JCB; Mousa H; Mahmoud F
Perm J; 2018; 22():17-181. PubMed ID: 30005721
[TBL] [Abstract][Full Text] [Related]
39. An investigator-initiated open-label clinical trial of vismodegib as a neoadjuvant to surgery for high-risk basal cell carcinoma.
Ally MS; Aasi S; Wysong A; Teng C; Anderson E; Bailey-Healy I; Oro A; Kim J; Chang AL; Tang JY
J Am Acad Dermatol; 2014 Nov; 71(5):904-911.e1. PubMed ID: 24929884
[TBL] [Abstract][Full Text] [Related]
40. Vismodegib for the treatment of basal cell carcinoma: results and implications of the ERIVANCE BCC trial.
Dessinioti C; Plaka M; Stratigos AJ
Future Oncol; 2014 May; 10(6):927-36. PubMed ID: 24941979
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
